LentiBOOST™
Maximise your virus uptake with transduction enhancers. Restricted uptake of virus particles often lowers the success of gene or short hairpin ribonucleic acid (shRNA) expression and requires the application of higher viral titers.
SIRION Biotech
Customised Viral Vectors for Cell Modelling, Gene Therapy, and Vaccination Research and Development
SIRION Biotech offers custom engineering of viral vectors to improve transduction and performance of in-vitro cell modelling, in-vivo gene modification and therapeutic research and development (R&D).
Am Klopferspitz 19,
82152 Martinsried,
Germany
SIRION Biotech offers custom engineering of viral vectors to improve transduction and performance of in-vitro cell modelling, in-vivo gene modification and therapeutic research and development (R&D).
The company’s virus-based technologies are used worldwide in academia and industry. SIRION’s strong focus on transduction technologies enables it to offer customisation services for all three major virus types, lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV).
Viral vector engineering and manufacture
SIRION engineers and manufactures replication-deficient LV, AAV and AV vectors. The platform offers many add-on options such as inducible expression systems, tissue-specific promoters and specialised transduction boosters for tight expression control.
Custom adeno-associated virus service
SIRION can manufacture a range of AAV serotypes and can engineer these with tissue-specific promotors to increase expression precision of nearly any gene of interest.
SIRION Biotech
Fast protein liquid chromatography (FPLC) grade AAV manufacture techniques provide high-purity products for R&D in less than eight weeks. The sophisticated platform allows the integration of desired expression constructs within the vector’s cloning capacity. Batch sizes range from 5×1011 genetic copies (GC) for small explorative experiments all the way to 5×1014 GC to satisfy complete experimental cohorts.
Additional in-house features of the SIRION AAV technology platform include capsid modifications to target cell-specific transduction. All projects are personally planned with highly trained project managers to ensure resulting vector designs and function fit the client’s intended application.
Custom lentivirus service
SIRION BIOTECH`s custom LV vector service enables the manufacture of constitutive and inducible gene vectors in less than four weeks.
SIRION’s multicistronic vector designs enable customers to create highly homogeneous, stable cell pools, and avoid time-consuming clone selection after transduction.
With the all-in-one inducible vector system, SIRION enables working with difficult cytotoxic genes and knockdown strategies. The manufacture of scales up to 1×109 TU is possible.
Custom adenovirus service
SIRION`s patented BAC technology enables AV construction in less than five weeks.
The system complies with standard safety criteria by using replication-deficient E1/E3 deleted serotype Ad5 as base vector. Desired genes or knockdown expression construct is possible, within a 7.5kb limit.
Transduction enhancers for difficult cell types
SIRION’s in-house developed transduction boosters enable working with difficult-to-transduce cell types such as hematopoietic cells.
The LentiBOOST™ reagent is currently used in several clinical trials to improve genetic modification of hematopoietic stem cells or T-cells for gene-therapy and chimeric antigen receptor T-cell (CAR-T) cell projects.
Developing novel AAV for gene therapy – NextGen AAV
AAVs are heavily utilised in modern gene therapy trials. While standard AAV applications are suitable for pre-clinical target validation and proof-of-principle experiments, they often fall short during the big step into clinical application.
SIRION´s AAV optimisation platform enables you to address AAV limitations before you take that crucial step. All elements of your AAV strategy are considered and optimised with your project’s specific goals in mind.
About SIRION Biotech
SIRION Biotech is a globally active technology provider with a strong customer base in the fields of cancer research, neurosciences, regenerative medicines, gene therapy, CAR T-cell development and R&D of new vaccination methods.
The company was founded in 2007 at the IZB in Martinsried near Munich, Germany. It was designed to shift the paradigm of viral vector technologies and supplies.
Today, the company has more than 500 ongoing projects. SIRION Biotech understands its customers’ technical challenges and offers specialised individual solutions for projects of all sizes.
Lentivirus
SIRION Biotech provides engineered Lentivirus vectors for gene expression and knockdown. Lentivirus vectors are the method of choice whenever a fast, efficient and cost-effective generation of stable cell models is required.
Adenovirus
SIRION Biotech’s engineered adenovirus vectors are used for transient and quantitative gene expression or knockdown.
Adeno-associated virus (AAV)
SIRION Biotech provides engineered adeno-associated virus (AAV) vectors for in-vivo gene expression and knockdown experiments, which help uncover the phenotypic impact of a genetic modification on the level of the living organism. AAVs are ideal for this kind of application.
NextGenAAV
SIRION Biotech offers full customisation services for gene therapy research and development (R&D). The company optimises adeno-associated virus (AAV) tissue specificity and immunogenic profiles.
Master Gene Copy Numbers in Hematopoietic Stem Cells
Transduction enhancers help increase the chances of success for blood-cell targeted gene therapies.
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.
SIRION Biotech Receives 2 Biotechnology Awards!
We are very excited about winning 2 Biotechnology awards from Global Health and Pharma (GHP).
Webinar: Engineering AAV Lead Vectors for Gene Therapy
The recombinant adeno-associated virus (rAAV) vector design affects not only the duration and localisation of the therapeutic sequence transcription, but also the manufacturing scalability and generation of manufacturing by-products, such as process and product-related impurities, that compromise the safety and efficacy of rAAV vector particles.
SIRION Biotech, Sanofi Partner to Revolutionise Gene Therapy Treatments
World leader in viral vector-based gene delivery technologies for gene & cell therapy, SIRION Biotech, is pleased to announce that it signed a license and collaboration agreement with global biopharmaceutical company Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors to realise effective gene therapy treatments for human major organ-affecting disorders.
Mustang Licenses Sirion’s Lentiboost™ for Lentiviral Gene Therapies
Sirion Biotech is pleased to announce that Mustang Bio is utilising its proprietary transduction enhancer, LentiBOOST™, in a pivotal Phase II clinical trial for MB-207 in X-linked severe combined immunodeficiency.
SIRION Biotech Licenses its LentiBOOST™ Transduction Technology to Cellectis
Through this license agreement, SIRION Biotech GmbH granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST™.
Mustang Bio Licenses LentiBOOSTTM Technology from SIRION Biotech
Mustang Bio Inc (Mustang) and SIRION Biotech GmbH (SIRION) are pleased that Mustang has acquired the rights to SIRION’s LentiBOOST™ technology for the development of MB-207.
SIRION Biotech Receives Gold Stevie Award Trophy
SIRION Biotech was thrilled to receive its trophy after winning a Gold Stevie Award at this year's American Business Awards, winning in the category Fastest Growing Company of the Year – Up to 100 Employees, after achieving record growth in the previous year.
AAV-Delivered Protective Antibodies Against SARSCoV-2
The Bavarian Research Foundation has recognised the development being made in continuous research by SIRION Biotech and the Erlangen University Hospital.
Viral Vector Engineering from SIRION Biotech
SIRION Biotech provides highly advanced viral vector technology, as well as vector manufacturing platforms established from lentiviruses, adenoviruses, and adeno-associated viruses (AAVs).
SIRION Achieves Gold Stevie Business Award
For its stellar performance during the past financial year, Sirion Biotech GmbH (SIRION), a specialist viral vector supplier, has been awarded a coveted Gold Stevie® American Business Award.
Why France is Leading the Gene and Cell Therapy Field in Europe
Europe is one of the largest gene and cell therapy markets in the world, with France and the UK at pole positions.
SIRION Biotech Licenses Technology to National Institute of Allergy and Infectious Diseases
SIRION Biotech has entered a license agreement with the National Institute of Allergy and Infectious Diseases (NIAID), which is part of leading clinical research institute the National Institutes of Health (NIH).
Key Candidate hAd19a/64 Outperforms Gold-Standard hAd5 as a Vaccine Vehicle
A recent collaboration between University of Copenhagen's associate professor Peter Johannes Holst, his research group, colleagues at Bogor Agricultural University, and Munich-based viral vector company SIRION Biotech demonstrated that key candidate hAd19a/64 can outperform counterpart and gold-standard hAd5 as a vaccine vehicle.
SIRION Biotech and Heidelberg University Hospital to Develop AAV Technologies
The viral vector specialist SIRION Biotech has announced the signing of a preferred partnership agreement with Heidelberg University Hospital and adeno-associated virus (AAV) pioneer Professor Dirk Grimm.
Sirion Biotech to Attend ESGCT XXV Anniversary Congress
Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society for Gene Therapy DG-GT.
CAR-T Acknowledged by FDA Committee
Novartis has announced its CAR-T cell therapy CTL019 has been recommended by the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC).
Sirion Biotech Viral Vector Experience
Gene delivery by viral vectors has taken centre stage in the development of gene therapies and immuno-oncologies. It has revolutionised the precision that complex cell models can be realised.
Viral Vectors Engineered for Academic and Clinical Research
Off-the shelf virus vectors are naturally limited to answer only a basic set of questions. This can lead experimenters to compromise their work.
Using Viral Vectors to Reach Higher Transduction Levels
Known as transduction, the application of virus particles to deliver gene constructs to a cell is one of the best and most efficient ways to genetically modify mammalian or human tissue.
Vaccunation and Immune Oncology Tool Ad19a/64 Acts as a Prime Reagent in a Two-Step Prime Boost Vaccination Approach
Sirion Biotech has announced that the Ad19a/64 vectors, considered by insiders as a promising vaccination and immune oncolgy tool, can act as a powerful prime reagent in a two-step prime boost vaccination approach.
SIRION BIOTECH GmbH
Am Klopferspitz 19
82152 Martinsried
Germany
